Tirzepatide may be on course to India but Eli Lilly and Company’s CEO, David Ricks, made clear that the enabling intellectual property rights (IPR) environment in the country isn't quite optimal.
The Lilly veteran referred to India’s “special moment” in the world amid geopolitical tailwinds but stressed that the country will...







